Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one (D30) is a synthetic small molecule and a derivative of pyromeconic acid. It has demonstrated antioxidant and anti-inflammatory properties in preclinical studies. D30 inhibits amyloid-beta aggregation, reduces neuroinflammation by downregulating galectin-3 expression, promotes amyloid-beta clearance from the brain, protects synapses, and improves cognitive function in mouse models of Alzheimer's disease. Its mechanism is similar to that of resveratrol but with distinct molecular targets including galectin-3 modulation[1][3][6]. The compound is being investigated primarily for its potential as a neuroprotective agent in Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one.